ProtoKinetix announced that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP and to date have shown no sign of irritation.
Based on this, ProtoKinetix is shipping AAGP to EyeCRO to commence testing dry eye disease efficacy. This testing will involve topical application of AAGP and evaluations of its effects on ocular inflammation.
EyeCRO is a specialized CRO in the field of preclinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.